1. Scrip
  2. >>Business

Roche Opens New Swiss R&D Center – And Maintains Genentech Independence

 
• By Andrew McConaghie

New hi-tech labs in Basel are aimed at boosting Roche’s R&D productivity, but despite streamlining in San Francisco, its twin-track drug discovery with Genentech will remain.

Roche pRED buildings
Roche hopes the new state-of-the-art facilities at the pRED Center in Basel will boost R&D productivity. • Source: Roche

Roche has unveiled a new upgrade to its pharma research and early development center (pRED) in Basel, Switzerland, aimed at boosting its drug discovery output and internal collaboration.

The company has invested CHF1.2bn ($1.4bn) in the creation of the new center, which introduces new time-saving technologies to help speed drug discovery, and brings together around 1,800 researchers in two high-rise laboratory buildings

Key Takeaways

  • Roche’s newest hit, ophthalmology treatment Vabysmo, was discovered in Basel, but the group has had less recent success in oncology

More from Business

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.